Accuray (ARAY) Scheduled to Post Quarterly Earnings on Thursday

Share on StockTwits

Accuray (NASDAQ:ARAY) will issue its quarterly earnings data after the market closes on Thursday, August 15th. Analysts expect the company to announce earnings of $0.03 per share for the quarter.

Shares of ARAY opened at $3.47 on Wednesday. The stock has a market capitalization of $313.37 million, a P/E ratio of -12.39 and a beta of 1.84. The business has a 50-day moving average of $3.81. The company has a quick ratio of 1.03, a current ratio of 1.71 and a debt-to-equity ratio of 3.06. Accuray has a 52 week low of $3.00 and a 52 week high of $5.40.

A number of equities analysts have issued reports on the company. BidaskClub downgraded Accuray from a “buy” rating to a “hold” rating in a research report on Tuesday, August 6th. BTIG Research reiterated a “hold” rating on shares of Accuray in a research report on Wednesday, April 24th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $5.13.

In other Accuray news, CEO Joshua Levine sold 56,426 shares of the stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $3.75, for a total transaction of $211,597.50. Following the transaction, the chief executive officer now owns 977,167 shares in the company, valued at $3,664,376.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Andrew J. Kirkpatrick sold 8,222 shares of the stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $3.75, for a total value of $30,832.50. Following the transaction, the insider now owns 232,414 shares in the company, valued at approximately $871,552.50. The disclosure for this sale can be found here. Corporate insiders own 3.40% of the company’s stock.

About Accuray

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.

Featured Story: Key terms to understand channel trading

Earnings History for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.